Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases: An NHLBI Resource for the Gene Therapy Community

Alice F. Tarantal^{1,2} and Sonia I. Skarlatos³

Abstract

The goals of the National Heart, Lung, and Blood Institute (NHLBI) Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases are to conduct gene transfer studies in monkeys to evaluate safety and efficiency; and to provide NHLBI-supported investigators with expertise, resources, and services to actively pursue gene transfer approaches in monkeys in their research programs. NHLBI-supported projects span investigators throughout the United States and have addressed novel approaches to gene delivery; “proof-of-principle”; assessed whether findings in small-animal models could be demonstrated in a primate species; or were conducted to enable new grant or IND submissions. The Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases successfully aids the gene therapy community in addressing regulatory barriers, and serves as an effective vehicle for advancing the field.

Introduction

SIGNIFICANT ADVANCES have been made toward the successful treatment of inherited diseases by gene transfer (Brantly *et al.*, 2009; Cartier *et al.*, 2009; Cavazzana-Calvo *et al.*, 2010; Ferrua *et al.*, 2010; Hacein-Bey-Abina *et al.*, 2010; Kohn, 2010; Perumbeti and Malik, 2010; Byrne *et al.*, 2011; Grez *et al.*, 2011; Bennett *et al.*, 2012; Corrigan-Curay *et al.*, 2012; High, 2012; Jacobson *et al.*, 2012; Scholler *et al.*, 2012). Among these are the more recent outcomes in clinical trials for Leber’s congenital amaurosis (Stein *et al.*, 2011; Bennett *et al.*, 2012), a form of inherited childhood blindness, and adenosine deaminase-deficient severe combined immune deficiency (ADA-SCID), an autosomal recessive disorder that alters lymphocyte development, survival, and function (Kohn, 2010; Corrigan-Curay *et al.*, 2012). Although the majority of clinical trials, to date, have not resulted in adverse findings, setbacks have occurred (Ott *et al.*, 2006), and it has been observed that integration of retroviral vectors near proto-oncogenes can lead to clonal dominance and leukemia (Hacein-Bey-Abina *et al.*, 2003; Hawkins *et al.*, 2011). Thus, there is a continued need to ensure long-term safety (Persons and Baum, 2011), which requires that investigators have access to relevant animal models, and the tools and resources

necessary to conduct the translational studies required to advance to human clinical trials.

Although all age groups can benefit from new molecular and cell-based therapies, the youngest patients may provide both unique advantages and additional challenges (“children are not small adults”). Because many inherited disorders can be identified prenatally, fetal gene transfer may provide the best time for treatment because early intervention may eliminate the pathology associated with disease. In addition, the functional immaturity of the fetal immune system can overcome the barrier of immune responses that complicates gene transfer postnatally and in adults (Brantly *et al.*, 2009; Mays and Wilson, 2011).

Animal models are essential to understand biological functions, study complex human diseases, and address safety of new therapies proposed for human use. Monkeys and humans share many features because of their close phylogenetic relationship; similarities in development, physiology, immunology, and anatomy aid in overcoming the roadblocks to clinical translation (Tanimura and Tanioka, 1975; Bontrop, 2001; Roth *et al.*, 2004; Tarantal, 2005; Shively and Clarkson, 2009; Sykes, 2009). For example, monkeys have been widely used as preclinical models for human bone marrow transplantation and stem cell gene therapy

¹Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases, California National Primate Research Center, University of California, Davis, Davis, CA 95616.

²Department of Pediatrics and Department of Cell Biology and Human Anatomy, University of California, Davis, Davis, CA 95616.

³National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.

(Trobridge and Kiem, 2010), and have shown substantial advantages when compared with other species. Long-term engraftment is challenging to assess in a short-lived mouse model, and differences between mouse and human host cell receptors may limit translation to the human clinical setting (Horn *et al.*, 2003; Mezquita *et al.*, 2008; Sykes, 2009; Beard *et al.*, 2010; Trobridge and Kiem, 2010; Gibbons and Spencer, 2011). Studies also indicate that the histology and time course for allograft rejection in monkeys parallel those in humans because of similarities in MHC genes and immune ontogeny (Bontrop, 2001; Sykes, 2009), and tolerance is much easier to achieve in mice (Mestas and Hughes, 2004). Thus, nonhuman primates can accelerate the development of promising new gene- and cell-based therapies for humans in all age groups.

Studies supported by the National Heart, Lung, and Blood Institute (NHLBI) Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases (California National Primate Research Center at the University of California, Davis, Davis, CA) have addressed gaps and roadblocks through a proven and highly effective program. The established infrastructure can rapidly test new paradigms, move new hypotheses and emerging gene transfer vectors into a preclinical setting, and provide critical preliminary data for new grants and investigational new drug (IND) submissions. Novel aspects of the program include the following: a strong track record in a collaborative team approach, strengths in translational research, unique capabilities in the study of fetal/pediatric nonhuman primate models of human development and disease, and the use of novel *in vivo* imaging modalities including positron emission tomography (PET) and bioluminescence imaging (BLI). The development and application of new *in vivo* imaging technologies have provided new ways to monitor long-term gene expression and the trafficking of transplanted cells in real time (Tarantal *et al.*, 2006, 2009, 2012c). The Center also highlights a state-of-the-art fetal therapy program with many ultrasound-related techniques and procedures that have been applied comparable to those used in humans (Tarantal, 2005).

Materials and Methods

Animals

All animal procedures conform to the requirements of the Animal Welfare Act, and protocols are approved before implementation by the Institutional Animal Care and Use Committee (IACUC) at the University of California, Davis. Normally cycling, adult female rhesus monkeys (*Macaca mulatta*) with a history of prior pregnancy are bred and identified as pregnant according to established methods (Tarantal, 2005). Pregnancy in the rhesus monkey is divided into trimesters by 55-day increments, with 0–55 days of gestation representing the first trimester, 56–110 days of gestation representing the second trimester, and 111–165 days of gestation the third trimester (term, 165±10 days). Activities related to animal care (diet, housing) are performed according to California National Primate Research Center standard operating procedures (SOPs). Newborns are typically delivered by cesarean section at term according to established protocols and raised in the gene therapy nursery for postnatal studies (Tarantal *et al.*, 2005). Animals in older age groups (juvenile to adult) are maintained under estab-

lished housing conditions with environmental enrichment based on SOPs and by study assignment.

Process

A call for proposals (Fig. 1) is circulated annually to NHLBI-supported investigators, posted on the Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases website (www.CFMGT.ucdavis.edu) and as a link on the American Society of Gene and Cell Therapy (ASGCT) website, and presented at national meetings. Applications are requested after review and approval of the submitted Letters of Intent. Those selected are invited to submit a five-page proposal that is evaluated for scientific merit, preliminary data to support studies in monkeys, and relevance to the Center and NHLBI missions. Proposals include the following format: (1) Specific Aims and Hypotheses, (2) Background and Significance, and (3) Experimental Plan. The abstract from the funded parent grant is requested and an NIH Biographical Sketch (Biosketch) is required for all participating investigators. Proposals are reviewed, ranked, and discussed at a formal meeting of a standing Scientific Advisory Committee, which includes leaders in the gene therapy field. Efforts are made to support as many high-quality proposals as are feasible, based on budgetary requirements. As investigators discuss their respective research projects, new methodologies, assays, and techniques are developed to accommodate their needs. Investigators have the opportunity to conduct studies from a distant site with all required analyses (e.g., flow cytometry, ELISAs, qPCR, immunohistochemistry) performed by Center personnel and data provided, or they may request serum or plasma samples or peripheral blood mononuclear cells (PBMCs) to perform specialized assays. A biorepository of control specimens (e.g., serum, plasma, cells, frozen or formalin-fixed tissues) are also available to NHLBI investigators on request.

Results and Discussion

A series of basic questions in gene delivery have been addressed including the efficiency of gene transfer using lentivirus (HIV or SIV) and adeno-associated virus (AAV) vectors to target specific cells and tissues; the potential effects of gene transfer on prenatal and postnatal development; the potential risk(s) to the fetus, infant, and dam; and the assessment of inadvertent germ-line transmission. Studies have also compared systemic and organ-targeted gene transfer approaches, and consistently shown high levels of transduction and transgene expression for extended periods of time (up to 10 years) without evidence of adverse effects. Examples of accomplishments include the following:

- Demonstrated systemic fetal administration of HIV-1-derived lentiviral and AAV vectors results in prolonged transgene expression in the muscular component of the diaphragm, with no evidence of adverse effects (Jimenez *et al.*, 2005a). These findings suggest the potential for fetal gene transfer to be developed into a durable therapeutic modality for the treatment of diseases for which only a small amount of protein is needed for correction (e.g., hemophilia)
- Showed that direct intrapulmonary and intramyocardial gene delivery results in persistent transgene expression

National Heart, Lung, and Blood Institute
CENTER FOR FETAL MONKEY GENE TRANSFER FOR HEART, LUNG, AND BLOOD DISEASES
REQUEST FOR PROPOSALS

Purpose: The Scientific Advisory Committee of the Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases located at the California National Primate Research Center at the University of California, Davis invites applications for projects to be conducted with monkeys during the current academic year.

Eligibility Requirements: Investigators with Principal Investigator status from any federally recognized institution with a funded grant supported by the National Heart, Lung, and Blood Institute (NHLBI) are invited to apply. Potential applicants are encouraged to contact Dr. Tarantal prior to submitting a letter of intent (aftarantal@primate.ucdavis.edu).

Application Procedures: A letter of intent including a short summary (no more than 1 page) with the title, aims and goals, and participating investigators, with a copy of the abstract of the funded NHLBI parent grant.

Complete proposals will be requested after initial review by the Scientific Advisory Committee and NHLBI program staff, using the following format:

- Specific Aims and Hypotheses
- Experimental Plan
- Background and Significance
- Rationale for Studies in Monkeys

The entire application should not exceed 5 pages, excluding NIH biographical sketches for all participating investigators. Budgetary information based on the needs of the study will be provided. Travel, equipment, and personnel costs are not permitted. Funds may not be used to provide support for any projects that qualify for support from other sources.

Review Criteria: Proposals will be evaluated for scientific merit, compatibility with the Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases mission, justification for using monkeys, and feasibility for conduct.

Examples of Services Available:

- Cell (autologous, allogeneic, xenogeneic) and gene transfer (systemic and organ-targeting)
- *In vivo* imaging including ultrasound, bioluminescence, and PET/CT (fetal to adult)
- Assays and related laboratory procedures including cell and tissue processing and cryopreservation, cell culture, quantitative PCR and RT-PCR, immunohistochemistry, *in situ* hybridization, immune- and hematopoietic-based assays (e.g., CFUs, LTC-IC), microscopy and stereology
- Immunophenotyping, immunoselection, and cell sorting
- Physiologic assessments (cardiovascular, pulmonary, hematopoietic)
- Consultation for protocol development, design, and implementation

FIG. 1. Annual call for Letters of Intent.

without evidence of adverse effects (Tarantal *et al.*, 2005). These studies support that the route and timing of vector administration are crucial for limited biodistribution to other anatomical sites

- Conducted extensive analysis of gonads after various routes of lentiviral vector administration prenatally and confirmed no evidence of germ cell gene transfer in males or with organ-targeted approaches (Lee *et al.*, 2005b; Tarantal *et al.*, 2005). These studies further support the importance of organ-targeting and vector design (Pacak *et al.*, 2006) to limit biodistribution
- Used SIV-based lentiviral vectors (Kahl *et al.*, 2008) to transduce young monkey CD34⁺ hematopoietic stem/progenitor cells for autologous transplantation, and used nonmyeloablative conditioning regimens such as busulfan and fludarabine (Kahl *et al.*, 2006; Tarantal *et al.*, 2012a)
- Addressed the role of overexpression of transforming growth factor- β_1 during fetal lung development, using an intrapulmonary gene transfer approach (Tarantal *et al.*, 2010), providing a new model to explore lung disease that may allow greater insight into human lung development
- Reported that AAV8-mediated hepatic gene transfer in infant monkeys is safe and efficient but less stable when compared with adolescent animals (Bell *et al.*, 2011; Wang *et al.*, 2011)
- Showed that *in utero* delivery of an AAV2/5-human FVII vector in the late third trimester confers therapeutic expression of human FVII at birth, which was maintained above baseline levels for at least 2 months, and

that readministration with capsid proteins of another serotype (AAV2/8) ~1 year after fetal gene delivery resulted in a further increase in plasma levels (Binny *et al.*, 2012)

- Evaluated stem and progenitor cell age-related differences (fetal through aged) and showed significant differences across the lifespan (e.g., endothelial, hematopoietic, mesenchymal) (Lee *et al.*, 2004, 2005a, 2006; Hacia *et al.*, 2008; Kim *et al.*, 2008; Shelley *et al.*, 2012)
- Developed *in vivo* imaging techniques (PET, BLI) (Tarantal *et al.*, 2006, 2009, 2012c; Tarantal and Lee, 2010) that demonstrated long-term gene expression, and showed engrafted foci of human cells at sites not appreciated by the collection of blood or bone marrow
- Showed high levels of firefly luciferase expression with no adverse effects up through ~8 years postnatal age when organ-targeted fetal gene transfer approaches were used (e.g., intrathoracic, intrapulmonary, intramyocardial, intraportal, intrahepatic; lentiviral vectors or AAV serotypes) (Fig. 2). Imaging findings also showed good correlations with outcomes at the tissue level (Tarantal *et al.*, 2009; Tarantal and Lee, 2010; Tarantal, unpublished data)

The Center for Fetal Monkey Gene Transfer has supported projects that provided data for new IND applications. Each aspect of the clinical development plan was facilitated by interactions with the Center and showed that this program aids the gene therapy community in addressing regulatory barriers. The leap from preclinical discovery to human subject research is challenging, and the support and resources provided by the Center are a crucial component in this process. Examples include the following:

- Studies that assessed the use of busulfan in young monkeys to model nonmyeloablative conditioning have been used to translate this approach into an ADA-SCID clinical trial. These and related preclinical, translational studies have also involved the production of high volumes of lentiviral vectors, which has been instrumental in moving vector production methods to the levels necessary for human clinical trials.
- Studies have been instrumental in achieving the overall goal of using AAV expression of human acid α -glucosidase (GAA) in patients with Pompe disease. Initial studies established the usefulness of AAV serotype 1 in rhesus monkey muscle, and the results of this study were included in an IND submission for the use of AAV in 3- to 14-year-old patients who have developed ventilator dependence. Studies in the Center also identified novel properties of AAV2/9 in skeletal and cardiac muscle, important for enabling an IND application. Each aspect of the clinical development plan for Pompe disease was facilitated by studies in monkeys (Smith *et al.*, 2012).
- A current ongoing study in young monkeys is focused on identifying a safe and robust AAV delivery method for regional limb gene transfer for patients with Duchenne muscular dystrophy and involves a side-by-side comparison of AAV9 with an engineered capsid that shows strong detargeting of liver and preferred transduction of heart and skeletal muscle (Mitchell *et al.*,

2010). BLI is used to investigate biodistribution and tropism; outcomes have been incorporated in a pre-IND submission.

- Through funds from another NIH institute, studies in monkeys assessed the safety and gene transfer efficiency of a lentiviral vector, which showed a lack of toxicity and no adverse events in fetal and juvenile monkeys. These studies were critical in gaining approval for an IND application and conducting the first-in-human trial of an expressed small interfering RNA (siRNA) in a lentiviral vector (DiGiusto *et al.*, 2010).

The Center has developed many techniques that are routinely used to aid investigators in the conduct of their studies. Examples include the following:

- Primers and probes for quantitative PCR (qPCR) to assess biodistribution (DNA and RNA) (Jimenez *et al.*, 2005a; Tarantal *et al.*, 2005, 2012a). Because of genomic homology, primer and probe sets based on human sequences may also amplify rhesus monkey genes, and thus the Center has developed a catalog of multiple sets of primers and probes that can distinguish between the species to meet the needs of various investigators and projects.
- Primer and probe sets to identify male DNA sequences (human or rhesus) in serum and tissues for the multi-copy testis-specific Y-encoded (TSPY) gene (high sensitivity), and to quantify the single-copy sex-determining region Y (SRY) gene by PCR (Jimenez and Tarantal, 2003a,b). The rhesus Y chromosome assays are used routinely to identify male sequences in maternal blood samples in early gestation (before sexual differentiation), to select dams for studies that are focused on diseases that are male-specific, or to balance sex ratios (Wang *et al.*, 2011).
- Human TSPY and SRY assays are also used to identify human cells in the rhesus host posttransplant and in parallel with techniques that detect human cells in monkey tissues using a human-specific centromere probe. These methods provide an efficient means to further analyze specimens by immunohistochemistry and antibodies that cross-react only with human specimens (Tarantal *et al.*, 2000, 2012b).

- Streamlined the process for rapid and accurate assessment of tissues that express transgenes such as the enhanced green fluorescent protein (eGFP) by performing whole tissue fluorescence imaging to identify regions for further assessment by qPCR or immunohistochemistry (Tarantal *et al.*, 2005).
- Adapted reporter systems, such as the gene for firefly luciferase and its substrate luciferin, for BLI and those that encode a phosphorylating enzyme (e.g., HSV-sr39TK) such that a radiolabeled substrate for the enzyme is trapped only in cells that express a reporter for PET imaging (Cherry, 2004; Tarantal *et al.*, 2006). The advantages of *in vivo* imaging include that each individual can be followed longitudinally in real time, conferring a large statistical advantage, and animal-to-animal variability is reduced as a confounding variable. Studies have also shown that *in vivo* BLI is highly effective for monitoring long-term gene expression, identifying foci of engrafted cells, and assessing cell trafficking when combined with PET (Tarantal *et al.*, 2012c).

In summary, the Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases is a unique resource that has served an important role in the gene therapy community by addressing essential questions in gene delivery and consistently providing investigators with opportunities to test new vector constructs and approaches that advance the field. The Center provides collaborative opportunities to aid investigators in pursuing studies in rhesus monkeys of all age groups to address crucial gaps and roadblocks, and to provide the data necessary for NIH grant submissions and IND applications. Monkeys are a challenging species and specialized expertise and resources are needed to effectively and safely conduct these studies. Any investigator funded by the NHLBI is eligible to submit a Letter of Intent requesting to conduct a study with monkeys or to obtain specimens (e.g., serum, cells, tissues) for *in vitro* investigations. The potential ramifications of gene delivery in humans underscores the importance of rigorous assessments of long-term gene expression and safety, and the Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases provides these opportunities to investigators nationally.

FIG. 2. Examples of a subset of animals transferred prenatally during the late first trimester with AAV2, AAV2/1, HIV, or SIV-based vectors that indicate long-term transgene expression (up to 6 years) without evidence of adverse effects. These animals have exhibited stable expression in the muscular component of the diaphragm and peritoneum (1×10^7 – 4×10^9 photons/sec [p/s]) when using the prenatal systemic (intraperitoneal) ultrasound-guided approach for fetal gene transfer.

Acknowledgments

The Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases is supported by NIH grants (HL069748 and HL085794) and by the California National Primate Research Center base operating grant (NIH grant RR00169 and OD011107).

Author Disclosure Statement

The authors have nothing to disclose.

References

- Beard, B.C., Trobridge, G.D., Ironside, C., *et al.* (2010). Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. *J. Clin. Invest.* 120, 2345–2354.
- Bell, P., Wang, L., Gao, G., *et al.* (2011). Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. *Mol. Genet. Metab.* 104, 395–403.
- Bennett, J., Ashtari, M., Wellman, J., *et al.* (2012). AAV2 gene therapy readministration in three adults with congenital blindness. *Sci. Transl. Med.* 4, 120ra15.
- Binny, C., McIntosh, J., Della Peruta, M., *et al.* (2012). AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. *Blood* 119, 957–966.
- Bontrop, R.E. (2001). Non-human primates: Essential partners in biomedical research. *Immunol. Rev.* 183, 5–9.
- Brantly, M.L., Chulay, J.D., Wang, L., *et al.* (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. *Proc. Natl. Acad. Sci. U.S.A.* 38, 16363–16368.
- Byrne, B.J., Falk, D.J., Pacak, C.A., *et al.* (2011). Pompe disease gene therapy. *Hum. Mol. Genet.* 20, R61–R68.
- Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., *et al.* (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. *Science* 326, 818–823.
- Cavazzana-Calvo, M., Payen, E., Negre, O., *et al.* (2010). Transfusion independence and *HMG2A* activation after gene therapy of human β -thalassaemia. *Nature* 467, 318–322.
- Cherry, S.R. (2004). *In vivo* molecular and genomic imaging: New challenges for imaging physics. *Phys. Med. Biol.* 49, R13–R48.
- Corrigan-Curay, J., Cohen-Haguenauer, O., O'Reilly, M., *et al.* (2012). Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. *Mol. Ther.* 20, 1084–1094.
- DiGiusto, D.L., Krishnan, A., Li, L., *et al.* (2010). RNA-based gene therapy for HIV with lentiviral vector-modified CD34⁺ cells in patients undergoing transplantation for AIDS-related lymphoma. *Sci. Transl. Med.* 2, 36ra43.
- Ferrua, F., Brigida, I., and Aiuti, A. (2010). Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. *Curr. Opin. Allergy Clin. Immunol.* 10, 551–556.
- Gibbons, D.L., and Spencer, J. (2011). Mouse and human intestinal immunity: Same ballpark, different players; different rules, same score. *Mucosal Immunol.* 4, 148–157.
- Greif, M., Reichenbach, J., Schwäble, J., *et al.* (2011). Gene therapy of chronic granulomatous disease: The engraftment dilemma. *Mol. Ther.* 19, 28–35.
- Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., *et al.* (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. *N. Engl. J. Med.* 348, 255–256.
- Hacein-Bey-Abina, S., Hauer, J., Lim, A., *et al.* (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. *N. Engl. J. Med.* 363, 355–364.
- Hacia, J.G., Lee, C.C., Jimenez, D.F., *et al.* (2008). Age-related gene expression profiles of rhesus monkey bone marrow-derived mesenchymal stem cells. *J. Cell Biochem.* 103, 1198–1210.
- Hawkins, T.B., Dantzer, J., Peters, B., *et al.* (2011). Identifying viral integration sites using SeqMap 2.0. *Bioinformatics* 27, 720–722.
- High, K.A. (2012). The gene therapy journey for hemophilia: Are we there yet? *Blood* [Epub ahead of print] DOI: 10.1182/blood-2012-05-423210.
- Horn, P.A., Thomasson, B.M., Wood, B.L., *et al.* (2003). Distinct hematopoietic stem/progenitor cells are responsible for repopulation in NOD/SCID mice compared with nonhuman primates. *Blood* 102, 4329–4335.
- Jacobson, S.G., Cideciyan, A.V., Ratnakaram, R., *et al.* (2012). Gene therapy for Leber congenital amaurosis caused by *RPE65* mutations: Safety and efficacy in 15 children and adults followed up to 3 years. *Arch. Ophthalmol.* 130, 9–24.
- Jimenez, D.F., and Tarantal, A.F. (2003a). Quantitative analysis of male fetal DNA in maternal serum of gravid rhesus monkeys (*Macaca mulatta*). *Pediatr. Res.* 53, 18–23.
- Jimenez, D.F., and Tarantal, A.F. (2003b). Fetal gender determination in early first trimester pregnancies of rhesus monkeys (*Macaca mulatta*) by fluorescent PCR analysis of maternal serum. *J. Med. Primatol.* 32, 315–319.
- Jimenez, D.F., Lee, C.I., Kohn, D.B., and Tarantal, A.F. (2005a). HIV-1-derived lentiviral vectors and fetal route of administration on transgene biodistribution and expression in rhesus monkeys. *Gene Ther.* 12, 821–830.
- Jimenez, D.F., Leapey, A.C., Lee, C.I., *et al.* (2005b). Fetal CD34⁺ cells in the maternal circulation and long-term microchimerism in rhesus macaques (*Macaca mulatta*). *Transplantation* 79, 142–146.
- Kahl, C.A., Tarantal, A.F., Lee, C.I., *et al.* (2006). Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. *Exp. Hematol.* 34, 369–381.
- Kahl, C.A., Cannon, P.M., Oldenburg, J., *et al.* (2008). Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors. *Gene Ther.* 15, 1079–1089.
- Kim, B.S., Lee, C.C., Christensen, J.E., *et al.* (2008). Growth, differentiation, and biochemical signatures of rhesus monkey mesenchymal stem cells. *Stem Cells Dev.* 17, 185–198.
- Kohn, D.B. (2010). Update on gene therapy for immunodeficiencies. *Clin. Immunol.* 135, 247–254.
- Lee, C.I., Kohn, D.B., Ekert, J.E., and Tarantal, A.F. (2004). Morphological analysis and lentiviral transduction of fetal monkey bone marrow-derived mesenchymal stem cells. *Mol. Ther.* 9, 112–123.
- Lee, C.I., Fletcher, M., and Tarantal, A.F. (2005a). Effects of age on the frequency, cell cycle, and lineage maturation of rhesus monkey (*Macaca mulatta*) CD34⁺ and hematopoietic progenitor cells. *Pediatr. Res.* 58, 315–322.
- Lee, C.I., Jimenez, D.F., Kohn, D.B., and Tarantal, A.F. (2005b). Fetal gene transfer using lentiviral vectors and the potential for germ cell transduction in rhesus monkeys. *Hum. Gene Ther.* 16, 417–425.
- Lee, C.C.I., Ye, F., and Tarantal, A.F. (2006). Comparison of growth and differentiation of fetal and adult rhesus monkey mesenchymal stem cells. *Stem Cells Dev.* 15, 209–220.
- Mays, L.E., and Wilson, J.M. (2011). The complex and evolving story of T cell activation to AAV vector-encoded transgene products. *Mol. Ther.* 19, 16–27.

- Mestas, J., and Hughes, C.C.W. (2004). Of mice and not men: Differences between mouse and human immunology. *J. Immunol.* 172, 2731–2738.
- Mezquita, P., Beard, B.C., and Kiem, H.-P. (2008). NOD/SCID repopulating cells contribute only to short-term repopulation in the baboon. *Gene Ther.* 15, 1460–1462.
- Mitchell, A.M., Nicolson, S.C., Warischalk, J.K., and Samulski, R.J. (2010). AAV's anatomy: Roadmap for optimizing vectors for translational success. *Curr. Gene Ther.* 10, 319–3409.
- Ott, M.G., Schmidt, M., Schwarzwaelder, K., *et al.* (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of *MDS1-EV11*, *PRDM16* or *SETBP1*. *Nat. Med.* 12, 401–409.
- Pacak, C.A., Mah, C.S., Thattallyath, B., *et al.* (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction *in vivo*. *Circ. Res.* 99, e3–e9.
- Persons, D.A., and Baum, C. (2011). Solving the problem of γ -retroviral vectors containing long terminal repeats. *Mol. Ther.* 19, 229–231.
- Perumbeti, A., and Malik, P. (2010). Therapy for β -globinopathies: A brief review and determinants for successful and safe correction. *Ann. N.Y. Acad. Sci.* 1202, 36–44.
- Roth, G.S., Mattison, J.A., Ottinger, M.A., *et al.* (2004). Aging in rhesus monkeys: Relevance to human health interventions. *Science* 305, 1423–1426.
- Scholler, J., Brady, T.L., Binder-Scholl, G., *et al.* (2012). Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Sci. Transl. Med.* 4, 132ra53.
- Shelley, W.C., Huang, L., Critser, P.J., *et al.* (2012). Changes in the frequency and *in vivo* vessel-forming ability of rhesus monkey circulating endothelial colony-forming cells across the lifespan (birth to aged). *Pediatr. Res.* 71, 156–161.
- Shively, C.A., and Clarkson, T.B. (2009). The unique value of primate models in translational research. *Am. J. Primatol.* 71, 715–721.
- Smith, B.K., Collins, S.W., Conlon, T.J., *et al.* (2012). Phase I/II trial of AAV1-GAA intra-diaphragmatic gene therapy for chronic respiratory failure in Pompe disease. (Submitted).
- Stein, L., Roy, K., Lei, L., and Kaushal, S. (2011). Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis. *Expert Opin. Biol. Ther.* 11, 429–439.
- Sykes, M. (2009). Hematopoietic cell transplantation for tolerance induction: Animal models to clinical trials. *Transplantation* 87, 309–316.
- Tanimura, T., and Tanioka, Y. (1975). Comparison of embryonic and foetal development in man and rhesus monkey. In: *Laboratory Animal Handbook 6: Breeding Simians for Developmental Biology*. (Laboratory Animals, London) pp. 205–233.
- Tarantal, A.F. (2005). Ultrasound imaging in rhesus and long-tailed macaques: Reproductive and research applications. In: *The Laboratory Primate* (Elsevier, Philadelphia) pp. 317–351.
- Tarantal, A.F., and Lee, C.C.I. (2010). Long-term luciferase expression monitored by bioluminescence imaging after AAV-mediated fetal gene delivery in rhesus monkeys (*Macaca mulatta*). *Hum. Gene Ther.* 21, 143–148.
- Tarantal, A.F., Goldstein, O., Barley, F., and Cowan, M.J. (2000). Transplantation of human peripheral blood stem cells into fetal rhesus monkeys (*Macaca mulatta*). *Transplantation* 69, 1818–1823.
- Tarantal, A.F., McDonald, R.J., Jimenez, D.F., *et al.* (2005). Intrapulmonary and intramyocardial gene transfer in rhesus monkeys: Safety and efficiency of lentiviral vectors for fetal gene delivery. *Mol. Ther.* 12, 87–98.
- Tarantal, A.F., Lee, C.C.I., Jimenez, D.F., and Cherry, S.R. (2006). Fetal gene transfer using lentiviral vectors: *In vivo* detection of gene expression by microPET and optical imaging in fetal and infant monkeys. *Hum. Gene Ther.* 12, 1254–1261.
- Tarantal, A.F., Lee, C.C.I., and Itkin-Ansari, P. (2009). Real-time bioluminescence imaging of macroencapsulated fibroblasts reveal allograft protection in rhesus monkeys (*Macaca mulatta*). *Transplantation* 88, 38–41.
- Tarantal, A.F., Chen, H., Shi, T., *et al.* (2010). Overexpression of TGF- β_1 in fetal rhesus monkey lung causes severe and progressive pulmonary fibrosis. *Eur. Respir. J.* 36, 907–914.
- Tarantal, A.F., Giannoni, F., Sumiyoshi, T., *et al.* (2012a). Non-myeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys. *Mol. Ther.* 20, 1033–1045.
- Tarantal, A.F., Lee, C.C.I., Batchelder, C.A., *et al.* (2012b). Radiolabeling and *in vivo* imaging of transplanted renal precursors differentiated from human embryonic stem cells in fetal rhesus monkeys (*Macaca mulatta*). *Mol. Imaging Biol.* 14, 197–204.
- Tarantal, A.F., Lee, C.C.I., Kukis, D.L., and Cherry, S.R. (2012c). Radiolabeling to monitor cell trafficking and engraftment of human peripheral blood stem cells by positron emission tomography (PET) in young rhesus monkeys. (Submitted).
- Trobridge, G.D. and Kiem, H.-P. (2010). Large animal models of hematopoietic stem cell gene therapy. *Gene Ther.* 17, 939–948.
- Wang, L., Bell, P., Lin, J., *et al.* (2011). AAV8-mediated hepatic gene transfer in infant rhesus monkeys (*Macaca mulatta*). *Mol. Ther.* 19, 2012–2020.

Address correspondence to:

Dr. Alice F. Tarantal
California National Primate Research Center
Pedrick and Hutchison Roads
University of California
Davis, CA 95616-8542

E-mail: aftarantal@primate.ucdavis.edu

Received for publication September 8, 2012;
accepted September 12, 2012.

Published online: September 13, 2012.